Sarepta Therapeutics (SRPT) EBIAT (2016 - 2025)
Historic EBIAT for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $196.9 million.
- Sarepta Therapeutics' EBIAT rose 294786.38% to $196.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $396.0 million, marking a year-over-year increase of 73728.78%. This contributed to the annual value of $235.2 million for FY2024, which is 14388.98% up from last year.
- Sarepta Therapeutics' EBIAT amounted to $196.9 million in Q2 2025, which was up 294786.38% from $159.0 million recorded in Q4 2024.
- In the past 5 years, Sarepta Therapeutics' EBIAT ranged from a high of $196.9 million in Q2 2025 and a low of -$516.8 million during Q1 2023
- In the last 5 years, Sarepta Therapeutics' EBIAT had a median value of -$48.1 million in 2021 and averaged -$72.1 million.
- Per our database at Business Quant, Sarepta Therapeutics' EBIAT crashed by 85615.14% in 2021 and then surged by 294786.38% in 2025.
- Sarepta Therapeutics' EBIAT (Quarter) stood at -$122.0 million in 2021, then increased by 10.44% to -$109.2 million in 2022, then skyrocketed by 141.79% to $45.7 million in 2023, then surged by 248.37% to $159.0 million in 2024, then rose by 23.79% to $196.9 million in 2025.
- Its EBIAT was $196.9 million in Q2 2025, compared to $159.0 million in Q4 2024 and $33.6 million in Q3 2024.